Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease

Chrysochoou, Stamatios; Kreft, Andreas; Schneider, Eberhard

doi:10.1155/2022/1840589

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tolerability and efficacy of siltuximab observed in our patient is in line with previous evidence from both clinical practice and investigational trials of siltuximab in patients with iMCD. 14 , 24 , 25 , 26 …”

Section: Discussionmentioning

confidence: 99%

A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report

Strach,

Kuszmiersz,

Chmura

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageIdiopathic multicentric Castleman disease (iMCD) is challenging to diagnose due to clinical similarities with other conditions, such as Still's disease. Once diagnosed, iMCD may be effectively managed with the anti‐interleukin‐6 antibody siltuximab.AbstractHere, we present the case of a 19‐year‐old Polish woman with persistent fever and enlarged lymph nodes and whose diagnosis remained inconclusive following initial clinical assessments and extensive laboratory analyses. The patient had subsequent complaints of joint pain and erythema which were suspicious of Still's disease and resolved with treatment with tocilizumab. Later, the progression of symptoms, such as lymphadenopathy, and elevated interleukin‐6 levels were consistent with Castleman disease, leading to the diagnosis of idiopathic multicentric Castleman disease seven years after the patient first reported symptoms. Treatment with the anti‐interleukin‐6 antibody siltuximab resulted in complete symptom resolution and normalization of inflammatory parameters. No adverse events were reported due to treatment with siltuximab.

show abstract